| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | IL11RA; Interleukin-11 receptor subunit alpha; IL-11 receptor subunit alpha; IL-11R subunit alpha; IL-11R-alpha; IL-11RA |
| Entrez GeneID | 3590 |
| WB Predicted band size | Calculated MW: 45 kDa; Observed MW: 45 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human IL11RA |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是三篇与IL-11 Receptor alpha抗体相关的代表性文献摘要(基于公开研究整理，具体作者和标题为示例性内容)：
---
1. **文献名称**: *Targeting IL-11 Receptor Alpha Inhibits Colorectal Cancer Progression*
**作者**: Smith J. et al.
**摘要**: 研究通过开发抗IL-11Rα单克隆抗体，在结直肠癌模型中验证其疗效。结果显示，抗体阻断IL-11/IL-11Rα信号通路可显著抑制肿瘤生长和转移，并降低下游STAT3磷酸化水平，提示其作为潜在抗癌疗法的前景。
2. **文献名称**: *Anti-IL-11Rα Antibody Attenuates Pulmonary Fibrosis in Mice*
**作者**: Chen L. et al.
**摘要**: 该研究在小鼠肺纤维化模型中测试了IL-11Rα抗体的治疗作用。抗体干预后，纤维化标志物(如胶原沉积和TGF-β表达)显著减少，同时肺功能改善，表明靶向IL-11Rα可能成为抗纤维化治疗的新策略。
3. **文献名称**: *IL-11 Receptor Alpha Blockade Suppresses Chronic Inflammation in Rheumatoid Arthritis*
**作者**: Müller R. et al.
**摘要**: 通过体外和关节炎动物模型实验，发现抗IL-11Rα抗体可抑制促炎细胞因子(如IL-6、TNF-α)释放，并减少关节破坏，为类风湿性关节炎的免疫治疗提供了新方向。
---
**注**：上述文献为示例，实际研究中建议通过学术数据库(如PubMed)检索最新及具体研究。如需精准文献，可提供关键词进一步筛选。
The IL-11 receptor alpha (IL-11Rα) is a key subunit of the interleukin-11 (IL-11) receptor complex, which mediates signaling of the IL-11 cytokine, a member of the IL-6 family. IL-11 binds to IL-11Rα, triggering its dimerization with the shared gp130 co-receptor to activate downstream pathways like JAK/STAT, MAPK, and PI3K/AKT. This signaling is involved in tissue regeneration, inflammation, and cancer progression. Overexpression of IL-11/IL-11Rα has been linked to fibrotic diseases, tumor growth, metastasis, and bone metabolism disorders, making it a therapeutic target.
IL-11Rα-specific antibodies are designed to block IL-11 signaling by competitively inhibiting ligand-receptor interactions or promoting receptor internalization. These antibodies, including monoclonal and humanized variants, have shown promise in preclinical models for reducing fibrosis, suppressing tumor proliferation, and mitigating inflammatory conditions like rheumatoid arthritis. However, challenges remain in optimizing specificity to avoid off-target effects and ensuring minimal toxicity due to IL-11's dual roles in homeostasis and disease. Current research focuses on developing bispecific antibodies or combining IL-11Rα inhibitors with other therapies to enhance efficacy. Further clinical validation is needed to translate these findings into safe, effective treatments.
×
